Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival
Work
Year: 2023
Type: article
Abstract: Treatment of patients with Mayo stage IIIb light chain (AL) amyloidosis remains challenging, and prognosis remains very poor. Mayo IIIb patients were excluded from the pivotal trial leading to the app... more
Source: Haematologica
Authors Sara Oubari, Ute Hegenbart, Renate Schoder, Maximilian Steinhardt, Μαρία Παπαθανασίου +10 more
Institutions University Hospital Heidelberg, Heidelberg University, Medical University of Vienna, Universitätsklinikum Würzburg, West German Heart and Vascular Center Essen +3 more
Cites: 29
Cited by: 19
Related to: 10
FWCI: 3.691
Citation percentile (by year/subfield): 100
Subfield: Molecular Biology
Domain: Life Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $2,157